| Overview |
| bs-18283R-Cy7 |
| LIN9 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Monkey |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LIN9 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 286826 |
| Q5TKA1 |
| Nucleus |
| TGS; BARA; TGS1; TGS2; Lin-9; BARPsv; Protein lin-9 homolog; HuLin-9; hLin-9; Beta subunit-associated regulator of apoptosis; TUDOR gene similar protein; Type I interferon receptor beta chain-associated protein; pRB-associated protein; LIN9 |
| Acts as a tumor suppressor. Inhibits DNA synthesis. Its ability to inhibit oncogenic transformation is mediated through its association with RB1. Plays a role in the expression of genes required for the G1/S transition. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz